Rachael Schneider
Acute Care · Dallas, TXNPI 1053593442
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,831 of the $20,153 with a category attached, or 73.6%. 32 manufacturers reported payments, led by Abbott at 29.6% of the total. Reporting peaked in 2022 at $6,726 and has fallen 81.9% since, to $1,219 in 2025. Among acute care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 404 payments — averaging $49.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Medtronic$4K
- Atricure, Inc.$2K
- Boston Scientific$2K
- Impulse Dynamics (USA) Inc.$1K
- Johnson & Johnson$973
- plus $5K from 26 others
What the payments were for
- Travel & lodging$5,32226%
- Food & beverage$14,83174%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 116 | $5,964 |
| Medtronic | 24 | $3,578 |
| Atricure, Inc. | 14 | $1,714 |
| Boston Scientific | 22 | $1,596 |
| Impulse Dynamics (USA) Inc. | 16 | $1,275 |
| Johnson & Johnson | 35 | $973 |
| E.r. Squibb & Sons, L.L.C. | 41 | $843 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $743 |
| Pfizer | 34 | $712 |
| Merck | 13 | $314 |
| AOP Health US, LLC | 1 | $275 |
| Sanofi-aventis U.S. LLC | 15 | $238 |
| Abiomed | 2 | $236 |
| Inspire Medical Systems, Inc. | 3 | $200 |
| AstraZeneca | 4 | $198 |
| Amgen | 5 | $191 |
| Novartis | 10 | $190 |
| Heartflow, Inc. | 3 | $168 |
| Janssen Scientific Affairs, LLC | 2 | $163 |
| ZOLL Respicardia, Inc. | 1 | $88 |
| Bridgebio Pharma, Inc. | 3 | $88 |
| Altathera Pharmaceuticals LLC | 2 | $75 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $73 |
| Philips North America LLC | 1 | $58 |
| Cardiovascular Systems Inc. | 2 | $51 |
| Novo Nordisk | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| Boehringer Ingelheim | 1 | $24 |
| Teleflex LLC | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Solventum Corporation | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$1,658
- WATCHMAN Access System$1,123
- SYNERGY ABLATION SYSTEM$986
- CARDIOMEMS$720
- EVERA MRI XT DR SURESCAN$713
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$673
- XARELTO$581
- Rapiblyk$550
- ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM$525
- AVEIR$452
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$375
- CAMZYOS$228
- VERQUVO$220
- Impella$177
- Inspire$145
- ANDEXXA$125
- Repatha$118
- Fortify Assura, Ellipse ICD$116
- HeartMate 3 Left Ventricular Assist Device$110
How this compares
$20,153 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 58 | $66,640 |
| XareltoRivaroxaban | 31 | $42,517 |
| EntrestoSacubitril/Valsartan | 12 | $8,125 |
| Propafenone Hcl ErPropafenone Hcl | 20 | $4,678 |
| SotalolSotalol Hcl | 153 | $4,056 |
| Propafenone Hcl | 39 | $1,768 |
| Amiodarone Hcl | 104 | $1,464 |
| Flecainide Acetate | 38 | $1,436 |
| Metoprolol Succinate | 23 | $457 |
| Rosuvastatin Calcium | 18 | $332 |
| Losartan Potassium | 24 | $186 |
| Metoprolol Tartrate | 22 | $183 |
| Lisinopril | 15 | $115 |
| Hydralazine Hcl | 12 | $104 |
| Carvedilol | 19 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $712 | $66,64058 claims |
| Johnson & JohnsonXarelto | $973 | $42,51731 claims |
| NovartisEntresto | $190 | $8,12512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.
Other acute care in Dallas
- Jennifer PilotteDallas$232K
- Amanda BradleyDallas$85K
- Martha LibertyDallas$28K
- Peter TriporoDallas$15K
- Mario PadillaDallas$13K
- Toni SmithDallas$10K
- Christie MorrisonSan Antonio$225K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
- Afton DickersonHouston$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.